Cyrus Hamidi, MD
Geriatric Medicine · Lutherville Timonium, MDNPI 1134102775
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,197, 2.0 times the $595 reported in 2019. Among geriatric medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- AbbVie$968
- AstraZeneca$892
- Novo Nordisk$860
- Takeda Pharmaceuticals U.S.A., Inc.$392
- GSK$364
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,371100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 76 | $1,159 |
| AbbVie(2 entities) | 60 | $968 |
| AstraZeneca | 45 | $892 |
| Novo Nordisk | 50 | $860 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $392 |
| GSK | 16 | $364 |
| Exact Sciences | 15 | $340 |
| Sumitomo Pharma America, Inc. | 11 | $245 |
| Pfizer | 10 | $191 |
| Amarin Pharma, Inc. | 6 | $134 |
| Amgen(2 entities) | 5 | $102 |
| Supernus Pharmaceuticals, Inc. | 5 | $93 |
| Phathom Pharmaceuticals, Inc. | 5 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $58 |
| Merck | 4 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| Harmony Biosciences LLC | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Astellas Pharma US Inc | 2 | $34 |
| Johnson & Johnson | 1 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Madrigal Pharmaceuticals | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Bausch Health US, LLC | 1 | $24 |
| Almatica Pharma LLC | 1 | $22 |
| Watermark Medical, Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$125
How this compares
$6,371 in reported general payments places this provider in the 90th percentile of 112 geriatric medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 44 | $54,396 |
| EliquisApixaban | 30 | $31,100 |
| JardianceEmpagliflozin | 24 | $30,127 |
| OzempicSemaglutide | 29 | $26,205 |
| MounjaroTirzepatide | 12 | $14,806 |
| FarxigaDapagliflozin Propanediol | 13 | $9,515 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $9,301 |
| JanuviaSitagliptin Phosphate | 15 | $8,479 |
| MultaqDronedarone Hcl | 11 | $8,248 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,516 |
| RestasisCyclosporine | 12 | $6,704 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,728 |
| Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine | 19 | $4,163 |
| Atorvastatin Calcium | 299 | $3,078 |
| Rosuvastatin Calcium | 118 | $2,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $860 | $80,60173 claims |
| PfizerEliquis, Premarin | $191 | $33,39641 claims |
| Lilly USA, LLCMounjaro | $1,159 | $14,80612 claims |
| GSKBreo Ellipta, Incruse Ellipta | $364 | $14,02925 claims |
| AstraZenecaFarxiga | $892 | $9,51513 claims |
| MerckJanuvia | $55 | $8,47915 claims |
| AbbVieRestasis | $968 | $6,70412 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $2,15177 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 geriatric medicine providers in Maryland.
Other geriatric medicine in Lutherville Timonium
- Sean LengBaltimore$412K
- Jocelyn El-SayedBaltimore$84K
- Joanne LynnChevy Chase$52K
- James LettRockville$33K
- Marcelino AlbuerneCatonsville$14K
- Lee MusherChevy Chase$13K
- Raman TuliGaithersburg$8K
- Bruce LeffBaltimore$7K
- Robert CooperBaltimore$7K
- Esther OhBaltimore$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.